Starling Oncology, Inc.
No SEC Form 4 filings for $STLN in the last 30 days.
See all $STLN insider activity →Needham raised its price target for Starling Oncology (NASDAQ:STLN) to $9.00, citing growth prospects and a positive outlook from a recent roadshow. The stock has gained 88% year-to-date, with Q2 revenue of $161.3M beating estimates. The company reported its second profitable quarter post-IPO, with revenue up 34.6% year-over-year and adjusted EBITDA turning positive.
Starling Oncology, Inc. (STLN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 1, 2026, Brad Hively notified Starling Oncology, Inc. (the “Company”) of his decision to not stand for re-elect
Hively Brad sold 298,853 shares of Starling Oncology, Inc. (STLN) at $6.51 ($1.95M total) on 2026-08-21 under a Rule 10b5-1 trading plan.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning STLN (Starling Oncology, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent STLN coverage spans insider activity, financial news and corporate actions.
Analyst upgrade and better-than-expected earnings suggest upside potential.
Board/committee reshuffling can affect governance oversight and near-term signaling, but the filing provides no operational or financial change.
Significant insider sell may signal negative sentiment; price could face short‑term pressure.
The financing provides liquidity for operations but adds debt; stock may react to terms and covenant structure.
Chernett Jorey purchased 12,000 shares of Starling Oncology, Inc. (TOI) at $6.54 on 2026-08-14.
AlphAI scores every news story that mentions STLN with an AI model for sentiment and relevance, and aggregates insider trades from Starling Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Needham raised its price target for Starling Oncology (NASDAQ:STLN) to $9.00, citing growth prospects and a positive outlook from a recent roadshow. The stock has gained 88% year-to-date, with Q2 revenue of $161.3M beating estimates. The company reported its second profitable quarter post-IPO, with revenue up 34.6% year-over-year and adjusted EBITDA turning positive.
2 min readStarling Oncology, Inc. (STLN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 1, 2026, Brad Hively notified Starling Oncology, Inc. (the “Company”) of his decision to not stand for re-elect
4 min readHively Brad sold 298,853 shares of Starling Oncology, Inc. (STLN) at $6.51 ($1.95M total) on 2026-08-21 under a Rule 10b5-1 trading plan.
1 min readStarling Oncology, Inc. (STLN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 20, 2026, Starling Oncology Management, Limited Liability Company, a wholly owned subsidiary of Starling Oncology, Inc. (“SOM, LLC”), entered into a Credit Agreement (the “Revolving Loan Agreement”) among SOM, LLC, su
2 min readChernett Jorey purchased 12,000 shares of Starling Oncology, Inc. (TOI) at $6.54 on 2026-08-14.
1 min readChernett Jorey purchased 18,000 shares of Oncology Institute, Inc. (DFPH) at $5.27 on 2026-07-21.
1 min readTopicus.com Inc. (TSXV:TOI) said it will release its second-quarter results on Aug. 5, 2026, after markets close. The company plans to publish the results via press release and post them on its website and on SEDARPlus. The announcement relates to its upcoming quarterly earnings.
1 min readBiotech and healthcare stocks hit 52-week highs on July 14, 2026. The Oncology Institute (TOI) reached $6.66 after repaying an $86 million senior convertible note and projecting 2026 revenue of $630 million to $650 million. Inhibikase (IKT) rose above $2.36 after a $50 million ATM sale. Alto Neuroscience (ANRO) hit $28.85 after a $100 million direct offering. Elevance (ELV) touched $434.38, guiding 2026 adjusted diluted EPS of at least $26.75. Privia (PRVA) hit $28.30, estimating 2026 GAAP reven
4 min readChernett Jorey purchased 15,000 shares of Oncology Institute, Inc. (TOI) at $5.85 on 2026-07-10.
2 min readB. Riley Securities named The Oncology Institute (TOI) its Best Idea from a May conference and reiterated a buy rating with an $8 price target. TOI refinanced $86M convertible debt due Aug 2027 using a $75M OrbiMed term loan and $11M cash, avoiding equity. B. Riley cites improved free cash flow and projects Q2 2026 revenue of $152.8M.
4 min read